Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
muvalaplin
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein(a) [Lp(a)] formation. It works by disrupting the initial non-covalent interaction between apolipoprotein(a) [apo(a)] and apolipoprotein B100 [apoB100], thereby preventing the disulfide bond formation necessary for Lp(a) assembly. Elevated Lp(a) levels are associated with increased risk of cardiovascular diseases, and muvalaplin is being developed as a first-in-class oral therapy to lower Lp(a). The drug is under development by Eli Lilly, primarily targeting patients at high risk for cardiovascular events due to elevated Lp(a)[1][3][4][7][8].
- Other names
- muvalaplin
02
Targets
ApoB-100 (Apolipoprotein B-100)
Beyond the preview
Go deeper on muvalaplin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on muvalaplin.